PROK Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 8.94%, SMA50 2.0%, SMA200 -0.11%). The stock’s 14-day RSI is 56.26 (neutral), while the ATR of 0.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -68.72% below its high and over 384.47% above its low. Average 10-day trading volume of 597.29 thousand shares is below the 3-month average of 978.11 thousand, indicating normal recent market interest.

Wall Street analysts project EPS growth of 8.37% annually over the next five years. The latest quarter delivered EPS of -$0.12. The next quarter is forecast at -$0.15. Next year's EPS is expected at -$11.12. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $12.00 to $1.00. The high target offers 442.99% upside. The low target suggests -54.75% downside. The mean target is $7.40. This offers 234.84% upside. ProKidney Corp. earnings surprise history is a mixed track record. The quarter that ended November 10, 2025, missed forecasts by 0.0%. The prior quarter beat by -7.14%. Over the last six quarters, Apple has recorded several small beats. These include -5.88% in August 09, 2024.

ProKidney Corp. has 134.99 million shares outstanding. The public float is 86.72 million shares, elevated short interest at 9.02% of float. This equals 8.69 million shares. The short ratio is 1.69 days. Institutional investors hold 42.8% of the float. Insiders own 28.84%. Control Empresarial de Capitales S.A. de C.V. holds 73.84 million shares, Legorreta Pablo G. has 22.62 million shares and Cowen Aaron has 6.28 million shares. Over the past six months, insider transactions show net selling. They sold 81.93 thousand shares across 2 transactions.

ProKidney Corp. (NASDAQ:PROK) closed at $2.21 USD, losing -$0.10 (-4.33%) from the previous close of $2.31. The stock is currently mid-range between its 52-week high and low $0.46 and $7.13. With a market capitalization of about $621.91 million, ProKidney Corp. is classified as a small-cap and shows higher-than-market volatility (beta ~1.82). Key stats such as the average daily volume over the past year has been around 1.02 million shares, volume is running light vs its 52-week average. Headquartered in Winston-Salem, NC, ProKidney Corp. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Bruce Culleton, the company employs approximately 204 people and listed since June 30, 2021. ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates.

ProKidney Corp. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.98. This means the shares are trading above this model’s fair value.

ProKidney Corp. (NASDAQ:PROK) shares are flat -4.46% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows ProKidney Corp. trading at a premium to the broader market with a P/E of -4.25. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $11.25, suggesting 409.05% upside. Our AI forecast model points to short-term strength (11.31% over two weeks), a medium-term fall (-87.33% over three months), and a longer-term gain (332.13% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that ProKidney Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 11.31%, with price expected at $2.46 by March 17, 2026, within a range of $2.38 to $2.55 3-Month Outlook: Projected fall of -87.33%, reaching $0.28 by June 01, 2026, with a range of $0.11 to $0.37. 1-Year Outlook: Projected gain of 332.13%, with price at $9.55 by March 03, 2027, within a range of $5.07 to $12.99.

ProKidney Corp. trades at a P/E ratio of -4.25, slightly below the S&P 500 average, with a price-to-sales ratio of 845.36 and a price-to-book ratio of -0.3 indicating negative book value, which may reflect financial stress. The P/FCF stands at -4.29, also above market averages.